STAT3 and non-small cell lung carcinoma: FXR inhibitor, Z-GS, showed a favorable therapeutic effect in decreasing FXR/IL-6/IL-6ST/p-STAT3 axis and treating FXRhigh NSCLC metastasis in mouse models in vivo.